SAN FRANCISCO, February 5, 2024 (Newswire.com) - Leading health technology company MentalHealth.com is pleased to announce the appointment of Jeff Smith to its Venture Advisory Team and as co-leader of digital operations.

The company's newly established Venture Advisory Team, comprised of seasoned business executives, accomplished tech entrepreneurs, and highly regarded healthcare professionals, works alongside leadership to drive business initiatives and uphold its people-first culture.

“Beyond his capacity as a proven digital strategist and marketing prodigy, Jeff Smith understands the challenges to mental well-being posed by the modern digital world,” says Patrick Nagle, Co-Founder of MentalHealth.com. “His compassionate, heart-centered approach will be instrumental in developing resources and services that guide people towards self-understanding and connection.”

Jeff Smith is a self-made entrepreneur, proven business leader, and accomplished healthcare founder. Alongside Co-Founder Abhilash Patel, he impressively led the rapid growth of San Diego-based Recovery Brands to its ultimate sale in 2015. Jeff Smith's journey began in homelessness as a child and has since led to the creation of industry-leading enterprises that consistently achieve annual organic traffic values exceeding $100M. His visionary leadership also played a pivotal role in facilitating M&A transactions totaling an impressive $220M. Jeff Smith has invested in more than 20 purpose-driven impact organizations, all aligned with his desire for a deeper understanding of ourselves, the world, and consciousness itself. Presently, Jeff Smith founded and co-led investments in Supermind Platforms, the driving force behind Psychedelics.com, where he proudly serves as CEO.

“As humanity struggles with disconnection and numbness, often seeking solace in substances and distractions, MentalHealth.com embarks on a crucial mission to support the well-being of billions worldwide," shared Jeff Smith. "I'm proud to stand with this exceptional team committed to seeking truth and practicing compassion. This is the path to a venture with meaning."

Jeff Smith joins previously announced appointees to the MentalHealth.com Venture Advisory Team, which includes Brian Trisler, Co-Founder of A Place for Mom, Fred Joyal and Gary Saint-Denis, Co-Founders of 1-800-DENTIST, and Abhilash Patel, Founder of Within Health. He will work alongside Co-Founder and Clinical Care Team Director, Dr. Jesse Hanson, PhD, and Public Oversight Committee Advisor, Ryan Hampton, with support from Co-Founder and CEO, Daniel Rivette.

About MentalHealth.com

MentalHealth.com is a health technology company guiding people towards self-understanding and connection. The company offers reliable resources, accessible services, and nurturing communities. Its mission involves educating, supporting, and empowering people in their pursuit of well-being.

Contact Information:
Stacey Bartlett
[email protected]
1-800-834-8587
Related Files
MentalHealth.com - Jeff Smith, Venture Advisory Team.pdf
MentalHealth.com - Jeff Smith, Venture Advisory Team.txt



Original Source: MentalHealth.com Appoints Co-Founder Jeff Smith to Venture Advisory Team and Digital Operations

CLS Health, the largest physician-owned and physician-led organization in Houston with more than 33 locations, emphasizes the satisfaction and empowerment of its physicians as a key element in delivering exceptional patient care.

HOUSTON, February 5, 2024 (Newswire.com) - CLS Health offers a model that has been strategically designed to help preserve physicians’ autonomy and prevent staff burnout. The multispecialty group addresses many unique, complex issues faced by independent physicians, including high operational costs, patient satisfaction, value-based care, collecting payments, and hiring/retaining qualified staff.  

As a multispecialty group, CLS Health provides an operational management support and resource program to empower physicians in providing patient care. It allows physicians to channel their focus on delivering quality healthcare without the burden of administrative duties. Dr. Abdul Moosa, Primary Care, states, “I did not become a physician to be corporate, I became a physician for people, and I want to maintain that happiness.” 

CLS Health aspires to transform private practices into profitable partnerships by guiding them through the transition to value-based care, enhancing financial viability, and ensuring sustained growth. The multispecialty group not only fosters a professional environment but also empowers physicians with financial autonomy.  

Dedicated to providing compassionate, comprehensive, and patient-centric healthcare, CLS Health places the well-being and needs of patients at the forefront. By fostering collaboration across disciplines, the multispecialty group strives for comprehensive care that leads to optimal patient outcomes. The patient-centric approach empowers healthcare providers to deliver exceptional care while fostering a sense of ownership in their roles. 

The flexibility shown by a multispecialty group such as CLS Health stands out meticulously because it is designed to cater to the unique needs of each medical practice.  

CLS Health emphasizes physician ownership, reserving this distinction exclusively for its physicians. Notably, CLS Health ensures care through the continuum, maintaining control over the entire patient journey — from primary care offices to specialists, hospitals, ICUs, LTAC, SNFs, and nursing homes. 

CLS Health multispecialty group’s mission aims to reshape the landscape of independent medical practices. By effectively addressing administrative challenges, fostering professional autonomy, and intensifying its focus on patient care, CLS Health stands at the forefront of redefining healthcare. 

Contact Information:
Isaiah Rincon
Media Relations Manager
[email protected]
832-557-3338

Maria Penaloza
[email protected]


Original Source: CLS Health Empowers Physicians with Operational Support

PROST Stroke Trial Results Published in JAMA Neurology

IRVINE, Calif., February 5, 2024 (Newswire.com) - WallabyPhenox, a global pioneer in stroke healthcare innovation, has announced the publication of PROST in JAMA Neurology. Visit JAMA Neurology to view the publication. Commenced in 2019, this clinical study marks a significant advancement in the treatment of strokes caused by large vessel occlusion (LVO), a condition contributing to severe disability and mortality worldwide.

Tackling the Global Impact of Acute Ischemic Stroke

Acute ischemic stroke, resulting from an obstruction in the arteries leading to the brain, is a leading cause of disability and the second leading cause of death globally. In the United States alone, AIS affects an estimated 800,000 individuals annually. The urgency for more effective treatments is underscored by the high incidence and impact of this condition.

A Novel Trial Design Sets a New Standard for Stroke Trials 

PROST, through a head-to-head comparison of the pRESET thrombectomy device with the Solitaire device, has established a new benchmark in the realm of stroke device trials. This randomized clinical trial, including 340 patients, has confirmed the non-inferiority of the pRESET device in achieving functional independence and overall disability reduction at 90 days. With 54.9% of patients in the pRESET group reaching functional independence, the study reinforces the device's role as a significant player in stroke care.  James Lago, WallabyPhenox CEO, said, “The confidence in our product design is second to none, and with PROST, we are giving physicians the confidence to treat patients with the highest level of evidenced-based medicine. It doesn’t stop with PROST, WallabyPhenox’s clinical leadership continues with the ongoing, high impact randomized clinical trials, DART and COATING.”

pRESET: A Safe and Effective Treatment Option

In terms of safety, the pRESET group recorded no incidences of either symptomatic intracranial hemorrhage (sICH) or embolization of new territory (ENT), a noteworthy finding in the treatment of LVO strokes. The efficacy of the device was further evidenced by 85.5% of patients treated with pRESET achieving eTICI 2b50 revascularization within three passes. These outcomes not only highlight the device's safety but also its effectiveness in restoring blood flow and reducing disability in patients with LVO stroke. Dr. Ricardo Hanel, a co-principal investigator in PROST, said, “The PROST trial marks a significant milestone in stroke research, being the first to conduct a randomized comparison of a novel stent-retriever technology against a well-established one. Results from PROST verify the safety and efficacy of pRESET and have led to an FDA Clearance with a reduction of disability claim for LVO patients known only to 3 devices in the US.” 

Subgroup Analysis and Future Research

The depth of data from the PROST trial provides a wealth of information for future research endeavors. “Now that the results have been published, it opens up the opportunity for secondary and sub-group analysis by other investigators that have greatly contributed to this study. The PROST body of data is important and will be impactful in further understanding efficacy in treating LVOs due to its high level of scientific rigor, large sample size, and real-world randomization,” said co-principal investigator, Dr. Raul Nogueira.

About WallabyPhenox

WallabyPhenox stands at the forefront of stroke healthcare research, with a steadfast commitment to enhancing patient outcomes. The company's focus on rigorous clinical trials and technological innovation continues to push the boundaries of stroke treatment, aiming to reduce the global burden of this life-altering condition. For additional information, visit Our Website and follow our Twitter(X) and LinkedIn.

Contact Information:
Bryan Rhodes
US Marketing Director
[email protected]
+1 (949) 353-0594


Original Source: WallabyPhenox Boldly Sets New Benchmark in Evidence-Based Medicine With the PROST Trial

Arrigo Medical Devices is set to showcase its latest advancements in healthcare technology and device manufacturing at MD&M West 2024.

ANAHEIM, Calif., February 2, 2024 (Newswire.com) - Arrigo Medical Devices, a leading provider of high-quality medical supplies and devices, is thrilled to announce its participation at Medical Design & Manufacturing (MD&M) West 2024, North America's premier medtech conference. This prestigious event will be held in California from February 6th to 8th, uniting top-tier medical device companies from across the continent and beyond in a comprehensive West Coast manufacturing showcase.

MD&M West stands as a beacon for the medical device industry, featuring over 1,600 booths across five co-located trade shows. This dynamic platform allows medical pioneers to display the latest in components, tools, and groundbreaking technologies essential for crafting life-saving medical devices. Arrigo Medical Devices is proud to be among the exhibitors at this event, known for fostering meaningful connections, facilitating industry-leading partnerships, and offering a wealth of educational sessions led by esteemed medical experts.

“As a family-owned business deeply rooted in the medical device sector, Arrigo Medical Devices is synonymous with unparalleled quality and reliability,” said Tony Arrigo, CEO of Arrigo Medical Devices. “Our participation at MD&M West underscores our commitment to advancing the medical device industry and dedication to providing solutions that save and improve lives worldwide.”

MD&M West 2024, co-located with four other shows focusing on automation, packaging, design, and plastics manufacturing, offers a unique opportunity to access a wide array of medical device parts, components, services, and insights.

Arrigo Medical Devices is a family-owned company dedicated to providing the medical industry with superior-quality medical supplies and devices. With a focus on innovation and reliability, Arrigo Medical Devices has quickly become a trusted name in healthcare, offering a wide range of products essential for effective medical care, including essential medical supplies such as guidewires, catheters, drapes, Tyvek pouches, and more, ensuring healthcare facilities are equipped with the finest devices.

###

For more news and information about Arrigo Medical Devices, please visit https://arrigomedical.com.

XXX

Contact Information:
Media Relations
Media Relations
[email protected]
(332) 233-5417


Original Source: Arrigo Medical Devices Will Be Exhibiting at MD&M West 2024

At HIMSS 2024, AGFA HealthCare will showcase how Enterprise Imaging accelerates imaging expansion, eases network integration and delivers geographic scalability.

MORTSEL, Belgium, February 2, 2024 (Newswire.com) - In Orlando, AGFA HealthCare is set to engage with IT innovators who can discover how its Enterprise Imaging Platform keeps the entire healthcare eco-system in flow: to multi-specialty physicians, IT specialists, management, and patients. Developing “imaging without barriers,” AGFA HealthCare will demonstrate its ability to leverage medical imaging across the care continuum, empowering clinicians to provide consistent delivery of patient care – anytime, anywhere.

Developed to enable location-agnostic image engagement, the Imaging Health Network™ (IHN) brings a unique approach with a one-of-a-kind connected experience - offering frictionless access and hassle-free collaboration. Enabling a newly orchestrated flow for physicians, including fast access to the patient’s imaging record, the IHN creates a cross-enterprise Imaging Health Record™ (IHR), which supports clinical history completeness and confidence and enables the patient’s road to wellness.

Supporting the HIMSS 2024 theme of “Creating Tomorrow’s Health,” AGFA HealthCare teams will empower IT leaders to navigate and pioneer in the vibrant landscape of modern healthcare technologies. Such innovations include:

• Streaming Client: Radiologists need images that display in near real-time, wherever they are. With our web-based technology, AGFA Enterprise Imaging makes images available in near real time, empowering all members of the care team to collaborate seamlessly. By enabling physicians to break free from geographic constraints, it supports imaging without barriers.
• SaaS: Software as a Service (SaaS) delivers benefits, including faster deployments, lower costs, reduced hardware and maintenance, enhanced scalability and integration, ease of use, remote accessibility, and reduced IT bottlenecks.
• Cloud Services: These customizable services seamlessly close the image management infrastructure gap, delivering a solution that is secure, scalable, and accessible; easy to maintain and use at a predictable cost.

Mark Burgess, President for North America at AGFA HealthCare, comments: 

“AGFA HealthCare is thrilled to be joining the HIMSS Conference and to showcase our innovative solutions. These include our Enterprise Imaging Cloud with AGFA HealthCare’s Streaming Client solutions, which are designed for physician efficiency while meeting the organization’s strategic, financial and operational goals.”

The latest generation of AGFA HealthCare Enterprise Imaging breaks the paradigm of routing data to the user and instead brings the "user to the data" via near real-time streaming technology – truly supporting “tomorrow’s health.” HIMSS 2024 attendees are invited to experience such innovations and our “life in flow” at AGFA HealthCare Booth #1860. Contact us for a conversation at your convenience.

About AGFA HealthCare

At AGFA HealthCare, we are transforming the delivery of care – supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates – channeling our experience and aspirations to all of our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation to our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.

AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. Imaging Health Network and Imaging Health Record are trademarks of Agfa HealthCare N.V. or its affiliates. All rights reserved. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.

Contact Information:
Jessica Baldry
Marketing Communications
[email protected]
+447583203971


Original Source: AGFA HealthCare is Set to Demonstrate 'Imaging Without Barriers' at HIMSS24